The codon context provides cis-acting immune evasion for the human papilloma virus (HPV) E6
- Aikaterini Thermou1,
- Chrysoula Daskalogianni1,
- Lixiao Wang2,
- Laurence Malbert-Colas1,
- Van-Trang Dinh3,
- Mathilde Lavigne1,
- Marc Blondel3,
- Robin Fahraeus1 and
- JUSTINE HABAULT1,4
- ↵* Corresponding author; email: justine.habault{at}inserm.fr
Abstract
Human papilloma viruses (HPV) are linked to cancers but how virus-carrying tumor cells express HPV-encoded antigens without attracting the immune system is still poorly understood. Here we show how low- and high-risk HPV types equally exploit a cis-acting mechanism to limit the translation of the E6 mRNA, reducing the production of antigenic peptide substrates for the major histocompatibility class I (MHC-I) pathway. Introducing particular combinations of preferable codons throughout the HPV-16 E6 mRNA promotes mRNA translation and production of antigenic peptide substrates in mammalian cells but has minimal impact on E6 synthesis in S. cerevisiae. Using a gradual synonymous codon exchange, we identified a codon series with a significant effect on E6 translation rate. Unexpectedly, changing four non-preferable codons to preferable codons in the wild-type sequence resulted in an approximate 50% reduction in E6 expression. However, five additional changes to preferable codon further upstream shifted this inhibition to a strong induction of E6 expression, while they had no effect when introduced alone. These findings suggest a nuanced relationship between tRNA pools and translation rate, emphasizing how HPV uses codon usage to evade immune detection.
Keywords
- Received January 13, 2025.
- Accepted August 26, 2025.
- Published by Cold Spring Harbor Laboratory Press for the RNA Society
This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.










